MA43815A - Stéroïdes neuroactifs, compositions, et leurs utilisations - Google Patents
Stéroïdes neuroactifs, compositions, et leurs utilisationsInfo
- Publication number
- MA43815A MA43815A MA043815A MA43815A MA43815A MA 43815 A MA43815 A MA 43815A MA 043815 A MA043815 A MA 043815A MA 43815 A MA43815 A MA 43815A MA 43815 A MA43815 A MA 43815A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- neuroactive steroids
- neuroactive
- steroids
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305279P | 2016-03-08 | 2016-03-08 | |
| US201662355174P | 2016-06-27 | 2016-06-27 | |
| US201662355669P | 2016-06-28 | 2016-06-28 | |
| US201662360762P | 2016-07-11 | 2016-07-11 | |
| US201662360758P | 2016-07-11 | 2016-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43815A true MA43815A (fr) | 2021-04-07 |
Family
ID=59789807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043815A MA43815A (fr) | 2016-03-08 | 2017-03-08 | Stéroïdes neuroactifs, compositions, et leurs utilisations |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20200306265A1 (fr) |
| EP (1) | EP3426257A4 (fr) |
| JP (3) | JP6838074B2 (fr) |
| KR (2) | KR102408399B1 (fr) |
| CN (2) | CN113616661A (fr) |
| AU (2) | AU2017229656B2 (fr) |
| BR (1) | BR112018067998A2 (fr) |
| CA (2) | CA3017172C (fr) |
| HK (1) | HK1258616A1 (fr) |
| IL (2) | IL300422A (fr) |
| JO (1) | JOP20170059B1 (fr) |
| MA (1) | MA43815A (fr) |
| MX (2) | MX2018010902A (fr) |
| PH (1) | PH12018501923A1 (fr) |
| RU (2) | RU2022102537A (fr) |
| SG (1) | SG11201807785VA (fr) |
| TW (2) | TWI798173B (fr) |
| WO (1) | WO2017156103A1 (fr) |
| ZA (1) | ZA201805905B (fr) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3572417A3 (fr) | 2011-10-14 | 2020-03-25 | Sage Therapeutics, Inc. | Composés de 19-nor prégnane disubstitués 3,3, compositions et leurs utilisations |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| IL304912A (en) | 2012-08-21 | 2023-10-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| EP2925327B1 (fr) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone pour le traitement, la reduction or l'adouccissement des symptômes de la dépression post partum |
| KR102239541B1 (ko) | 2013-04-17 | 2021-04-14 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2014169836A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci |
| RU2700264C2 (ru) | 2013-04-17 | 2019-09-16 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| EP3868382A1 (fr) | 2013-07-19 | 2021-08-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions et leurs utilisations |
| LT3488852T (lt) | 2013-08-23 | 2021-02-25 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, kompozicijos, ir jų naudojimas |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| LT3206493T (lt) | 2014-10-16 | 2020-08-25 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
| BR112017007902B1 (pt) | 2014-10-16 | 2023-12-05 | Sage Therapeutics, Inc | Composto e seu sal, composição farmacêutica e uso do referido composto e seu sal na fabricação de um medicamento para o tratamento de distúrbios do sistema nervoso central |
| SI3224269T1 (sl) | 2014-11-27 | 2020-10-30 | Sage Therapeutics, Inc. | Sestavki in metode za zdravljenje CNS motenj |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| WO2017156103A1 (fr) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| DK3481844T3 (da) | 2016-07-11 | 2024-07-22 | Sage Therapeutics Inc | C7, C12 og C16 substituerede neuroaktive steroider og disses fremgangsmåder til anvendelse |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| PE20190915A1 (es) | 2016-08-23 | 2019-06-26 | Sage Therapeutics Inc | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino |
| EP3579842A4 (fr) * | 2017-02-10 | 2020-12-23 | Asarina Pharma AB | 3-bêta-hydroxy-5-alpha-prégnan-20-one destinée à être utilisée dans le traitement des tremblements essentiels |
| IL303250A (en) * | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| WO2019075362A1 (fr) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | Méthode de traitement de troubles du système nerveux central avec des neurostéroïdes et des composés gabaergiques |
| AU2018364659A1 (en) * | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| WO2019113494A1 (fr) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MX2020008182A (es) * | 2018-02-11 | 2020-09-22 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos. |
| MA52894A (fr) * | 2018-06-12 | 2021-04-21 | Sage Therapeutics Inc | 19-nor stéroïde c21-n-pyrazolyle disubstitué en c3,3 et procédés d'utilisation de celui-ci |
| JP2022511673A (ja) * | 2018-11-05 | 2022-02-01 | オービッド・セラピューティクス・インコーポレイテッド | 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用 |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| KR20210116523A (ko) * | 2019-01-14 | 2021-09-27 | 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 | 테트라졸론 치환된 스테로이드 및 이의 용도 |
| US11497754B2 (en) | 2019-02-05 | 2022-11-15 | Washington University | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions |
| US20220125803A1 (en) * | 2019-03-04 | 2022-04-28 | Praxis Precision Medicines, Inc. | Methods for the treatment of perimenopause and menopause |
| WO2020243488A1 (fr) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et compositions associées |
| MX2022001553A (es) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolona para su uso en el tratamiento del estado epileptico. |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| KR20220134529A (ko) * | 2019-12-06 | 2022-10-05 | 마리누스 파마슈티컬스 인코포레이티드 | 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론 |
| AU2021206712A1 (en) * | 2020-01-12 | 2022-07-28 | Brii Biosciences, Inc. | Neuroactive steroids and pharmaceutical composition containing the same |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| EP4255438A4 (fr) * | 2020-12-07 | 2024-10-16 | Marinus Pharmaceuticals Inc | Utilisation de la ganaxolone dans le traitement d'un trouble épileptique |
| CN112516086B (zh) * | 2020-12-08 | 2022-05-20 | 武汉久安药物研究院有限公司 | 注射用布瑞诺龙脂肪乳及其制备方法 |
| US20240122945A1 (en) * | 2021-01-28 | 2024-04-18 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| BR112023021131A2 (pt) * | 2021-04-12 | 2023-12-19 | Sage Therapeutics Inc | Tratamento de tremor essencial |
| US11337987B1 (en) * | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
| MX2024001372A (es) | 2021-07-28 | 2024-02-27 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo. |
| WO2023146579A1 (fr) * | 2022-01-27 | 2023-08-03 | Belnap Pharmaceuticals, Llc | Méthodes de traitement mettant en oeuvre l'oxytocine |
| WO2023164385A1 (fr) * | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs pour le traitement de maladies ou d'états gastro-intestinaux |
| WO2023211856A1 (fr) * | 2022-04-26 | 2023-11-02 | Praxis Precision Medicines, Inc. | Méthodes de traitement de troubles neurologiques |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| WO2024059608A1 (fr) * | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs deutérés |
| CN115957332B (zh) * | 2022-11-01 | 2023-10-10 | 北京华睿鼎信科技有限公司 | 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用 |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3117142A (en) | 1961-03-01 | 1964-01-07 | Roussel Uclaf | Novel preparation of estradiol and estrone |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3865939A (en) | 1973-02-23 | 1975-02-11 | Procter & Gamble | Edible oils having hypocholesterolemic properties |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| SE8600632D0 (sv) | 1986-02-13 | 1986-02-13 | Kabivitrum Ab | Novel pharmaceutical composition |
| US5120723A (en) * | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| AU2657292A (en) | 1991-09-13 | 1993-04-27 | Cocensys, Inc. | Novel gabaa receptor with steroid binding sites |
| EP0701444B1 (fr) | 1993-05-24 | 2010-04-07 | Purdue Pharma Ltd. | Procedes et compositions induisant le sommeil |
| EP0656365B1 (fr) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Dérivés 2-bêta-morpholino de androstane |
| ES2296594T3 (es) | 1994-02-14 | 2008-05-01 | Euro-Celtique S.A. | Androstanos y pregnanos para la modulacion alosterica del receptor de gaba. |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| KR100394548B1 (ko) | 1994-11-23 | 2004-02-05 | 퍼듀 파머 리미티드 | Gaba수용체의알로스테릭조절을위한안드로스탄및프레그난계열화합물 |
| US6780853B1 (en) | 1995-06-06 | 2004-08-24 | Euro-Celtique S.A. | Neuroactive steroids of the androstane and pregnane series |
| DE69634039T2 (de) | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| WO1997003677A1 (fr) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition de l'activite des recepteurs du n-methyl-d-aspartate au moyen de derives de sulfate de pregnenolone |
| WO1998005337A1 (fr) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Utilisation de ligands de recepteurs gaba et nmda pour le traitement des cephalees de la migraine |
| US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
| US6245757B1 (en) | 1997-10-03 | 2001-06-12 | Research Corporation Technologies, Inc. | Use of progestins to treat ischemic event |
| ATE307592T1 (de) | 1998-03-11 | 2005-11-15 | Torbjoern Backstroem | Epiallopregnanolon zur behandlung von krankheiten des cns |
| US20020198174A1 (en) | 2001-05-07 | 2002-12-26 | Allergan Sales, Inc. | Disinfecting and solubilizing steroid compositions |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| DK1104760T3 (da) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020072509A1 (en) | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| AU2002250064B2 (en) | 2001-02-13 | 2008-01-17 | University Of Florida Research Foundation, Inc. | A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| ES2316571T3 (es) | 2001-05-24 | 2009-04-16 | Alexza Pharmaceuticals, Inc. | Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria. |
| US20030032638A1 (en) | 2001-05-24 | 2003-02-13 | Kim John J. | Delivery of benzodiazepines through an inhalation route |
| JP2003063965A (ja) | 2001-06-13 | 2003-03-05 | Otsuka Pharmaceut Factory Inc | 注射用シロスタゾール水性製剤 |
| CA2496867A1 (fr) | 2002-08-28 | 2004-03-11 | Hollis-Eden Pharmaceuticals, Inc. | Procedes de traitement therapeutique |
| US9339508B2 (en) | 2003-01-17 | 2016-05-17 | Mapreg | Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury |
| WO2005000869A1 (fr) | 2003-05-29 | 2005-01-06 | Washington University | 13,24-cyclo-18,21-dinorcholanes neuroactifs et steroides pentacycliques structurellement associes |
| US7816074B2 (en) | 2003-07-31 | 2010-10-19 | The Research Foundation Of State University Of New York | α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| EP1574222B1 (fr) | 2004-03-12 | 2011-02-09 | Cipla Ltd. | Procédé de stérilisation pour stéroïdes |
| WO2005105822A2 (fr) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | Procede de fabrication de steroides 3-alpha-hydroxy sustitues, nouveaux derives de steroides et leurs applications |
| US20060063707A1 (en) | 2004-09-17 | 2006-03-23 | Lifelike Biomatic, Inc. | Compositions for enhancing memory and methods therefor |
| WO2006037016A2 (fr) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Nouvelle therapie destinee au traitement de maladies cerebrales degeneratives chroniques et d'une lesion du systeme nerveux |
| CA2582231A1 (fr) | 2004-09-29 | 2006-10-19 | Hollis-Eden Pharmaceuticals, Inc. | Analogues de steroides et leurs utilisations |
| KR20070112164A (ko) | 2005-02-15 | 2007-11-22 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 벤조디아제핀의 에어로졸과 주사가능한 제제 |
| AU2006226774B2 (en) | 2005-03-24 | 2010-12-02 | Emory University | Methods for the treatment of central nervous system injury via a tapered administration of progesterone |
| JP2008538748A (ja) | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
| US20110319386A1 (en) | 2005-08-26 | 2011-12-29 | Braincells Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1959966B1 (fr) | 2005-11-28 | 2020-06-03 | Marinus Pharmaceuticals, Inc. | Formes galéniques de ganaxolone et procédés de preparation et d'utilisation de celles-ci |
| US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
| MX2008014840A (es) * | 2006-05-22 | 2008-12-05 | Vanda Pharmaceuticals Inc | Tratamiento de trastornos depresivos. |
| JP2010502722A (ja) | 2006-09-08 | 2010-01-28 | ブレインセルス，インコーポレイティド | ４−アシルアミノピリジン誘導体を含む組み合わせ |
| US20090239942A1 (en) | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US20090074677A1 (en) | 2007-01-08 | 2009-03-19 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| US7813811B2 (en) | 2007-02-08 | 2010-10-12 | Neuropace, Inc. | Refillable reservoir lead systems |
| CN101678025A (zh) | 2007-04-11 | 2010-03-24 | 生物马林药物股份有限公司 | 四氢生物蝶呤组合物及其测量方法 |
| US8530463B2 (en) | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| US8969329B2 (en) | 2007-06-11 | 2015-03-03 | University Of Southern California | Allopregnanolone in a method for enhancing neurological function |
| WO2008157460A1 (fr) | 2007-06-15 | 2008-12-24 | Cook, Kevin, M. | Steroides d'androstane et de pregnane presentant de puissantes proprietes de modulation allosterique du complexe recepteur gaba/ionophore chlorure |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| EP2175886A1 (fr) | 2007-06-28 | 2010-04-21 | CNSBio Pty Ltd | Procédés et compositions de combinaison pour le traitement d'une douleur neuropathique |
| US20100297181A1 (en) | 2007-12-26 | 2010-11-25 | Eisai R&D Management Co., Ltd. | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ |
| BRPI0821970A2 (pt) | 2008-01-03 | 2015-06-23 | Biomarin Pharm Inc | Análogos de pterina para tratamento de condição responsiva a bh4 |
| US20090198145A1 (en) | 2008-02-06 | 2009-08-06 | Chow Harrison | Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| US8729070B2 (en) | 2008-02-20 | 2014-05-20 | Targia Pharmaceuticals | CNS pharmaceutical compositions and methods of use |
| CZ301216B6 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| EP2356109B1 (fr) | 2008-10-10 | 2016-12-07 | VM Discovery, Inc. | Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies |
| CN102300566A (zh) | 2008-11-30 | 2011-12-28 | O·扎查尔 | 血管收缩剂的皮肤应用 |
| EP2376072A1 (fr) * | 2008-12-29 | 2011-10-19 | Tartu Ülikool (University Of Tartu) | Inhibiteurs de l'arginase pour le traitement de la dépression |
| US20110306579A1 (en) | 2009-01-30 | 2011-12-15 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
| US20120142645A1 (en) | 2009-03-17 | 2012-06-07 | Marx Christine E | Neuroactive steroid compositions and methods of use for lowering cholesterol |
| US20110152840A1 (en) * | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| KR101747476B1 (ko) | 2010-01-21 | 2017-06-14 | 드로브리지 파마슈티컬스 피티와이 엘티디 | 마취 제제 |
| EP2635333B1 (fr) | 2010-11-03 | 2014-09-03 | Sanofi-Aventis Deutschland GmbH | Canule à aiguille contenant un médicament |
| WO2012075286A2 (fr) | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Benzodiazépine intrapulmonaire pour traitement et prévention de crises épileptiques |
| CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| WO2012116290A2 (fr) | 2011-02-25 | 2012-08-30 | Washington University | Stéroïdes neuroactifs substitués par 17(20)-z-vinylcyano, promédicaments de ceux-ci et procédés de traitement les utilisant |
| FR2973031B1 (fr) | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
| JP5893135B2 (ja) | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| CA2843436A1 (fr) * | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Nouveaux steroides substitues en 17? par un heteroaryle, capables de moduler les recepteurs gabaa |
| DK2753632T3 (da) * | 2011-09-08 | 2023-07-10 | Sage Therapeutics Inc | Neuroaktive steroider, sammensætninger og anvendelse heraf |
| WO2013043985A1 (fr) * | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Huiles comestibles favorisant l'administration de stéroïdes administrés par voie orale |
| EP3572417A3 (fr) | 2011-10-14 | 2020-03-25 | Sage Therapeutics, Inc. | Composés de 19-nor prégnane disubstitués 3,3, compositions et leurs utilisations |
| CA2856599C (fr) | 2011-11-29 | 2017-05-30 | Amino Up Chemical Co., Ltd. | Composition comprenant de la vicenine-2 ayant un effet benefique sur la fonction neurologique et/ou cognitive |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2013188792A2 (fr) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| WO2014028398A2 (fr) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes |
| IL304912A (en) | 2012-08-21 | 2023-10-01 | Sage Therapeutics Inc | Treatment methods for epilepsy and status epilepticus |
| WO2014058736A1 (fr) | 2012-10-08 | 2014-04-17 | Washington University | Stéroïdes neuroactifs 19-alcoxy-17(20)-z-vinylcyano-substitués, promédicaments associés et méthodes de traitement les utilisant |
| WO2014071449A1 (fr) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Stéroïdes neuroactifs et leur utilisation pour faciliter la neuroprotection |
| EP2925327B1 (fr) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone pour le traitement, la reduction or l'adouccissement des symptômes de la dépression post partum |
| MX365644B (es) | 2012-12-18 | 2019-06-10 | Univ Washington | Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos. |
| WO2014108808A2 (fr) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Formulations pharmaceutiques pour le traitement et la prévention de la neuropathologie et de la neurodégénérescence induites par un traumatisme |
| KR102239541B1 (ko) | 2013-04-17 | 2021-04-14 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| RU2700264C2 (ru) | 2013-04-17 | 2019-09-16 | Сейдж Терапьютикс, Инк. | 19-нор нейроактивные стероиды и способы их применения |
| WO2014169836A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci |
| EP3868382A1 (fr) | 2013-07-19 | 2021-08-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions et leurs utilisations |
| LT3488852T (lt) | 2013-08-23 | 2021-02-25 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai, kompozicijos, ir jų naudojimas |
| ES2927007T3 (es) * | 2014-05-29 | 2022-10-31 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| US10246482B2 (en) * | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN107427458A (zh) | 2015-02-06 | 2017-12-01 | 马瑞纳斯制药公司 | 静脉内加奈索酮制剂及其在治疗癫痫持续状态和其他癫痫发作病症中的用途 |
| GB2541015A (en) | 2015-08-06 | 2017-02-08 | Ge Oil & Gas Uk Ltd | Subsea flying lead |
| US20180235916A1 (en) | 2015-10-14 | 2018-08-23 | The Regents Of The University Of California | Enhancing beta cell replication and/or survival |
| WO2017156103A1 (fr) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US20180050107A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Neurosteroid compositions and methods of use thereof |
| US20180050005A1 (en) | 2016-08-16 | 2018-02-22 | Janssen Pharmaceutica Nv | Concentrated Solution of 17-Hydroxydocosahexaenoic Acid |
| CN110072523A (zh) | 2016-09-07 | 2019-07-30 | 格利亚有限责任公司 | 通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| WO2018169798A1 (fr) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Atténuation de troubles du snc par polythérapie faisant intervenir des neurostéroïdes, et des bloqueurs ampa |
| KR20190137839A (ko) | 2017-04-18 | 2019-12-11 | 마리누스 파마슈티컬스 인코포레이티드 | 지속 방출 주사용 뉴로스테로이드 제제 |
| US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| US11752115B2 (en) | 2017-06-21 | 2023-09-12 | The Board Of Trustees Of The University Of Illinois | PPAR-alpha agonist treatment of neuropsychiatric disorders |
| US11266663B2 (en) | 2017-06-23 | 2022-03-08 | The Board Of Trustees Of The University Of Illinois | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| EP3642206A4 (fr) | 2017-06-23 | 2021-04-07 | The Regents of The University of California | Amélioration de la capacité de gaba pour moduler des réponses immunitaires |
| AU2018364659A1 (en) | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| UY38213A (es) | 2018-05-04 | 2019-10-31 | Acerus Pharmaceuticals Corp | Derivados de neuroesteroides y usos de estos |
| JP2022506944A (ja) | 2018-11-08 | 2022-01-17 | ヴァーソナ セラピューティクス，インコーポレーテッド | ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用 |
| US11123332B2 (en) | 2018-11-21 | 2021-09-21 | Certego Therapeutics Inc. | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| EA202191378A1 (ru) | 2018-12-14 | 2021-10-04 | Ацерус Биофарма Инк. | Активные сложноэфирные производные тестостерона, их композиции и применения |
-
2017
- 2017-03-08 WO PCT/US2017/021325 patent/WO2017156103A1/fr active Application Filing
- 2017-03-08 EP EP17763984.6A patent/EP3426257A4/fr active Pending
- 2017-03-08 IL IL300422A patent/IL300422A/en unknown
- 2017-03-08 JP JP2018546817A patent/JP6838074B2/ja active Active
- 2017-03-08 BR BR112018067998-4A patent/BR112018067998A2/pt not_active Application Discontinuation
- 2017-03-08 TW TW106107640A patent/TWI798173B/zh active
- 2017-03-08 MX MX2018010902A patent/MX2018010902A/es unknown
- 2017-03-08 US US16/083,339 patent/US20200306265A1/en not_active Abandoned
- 2017-03-08 SG SG11201807785VA patent/SG11201807785VA/en unknown
- 2017-03-08 CN CN202110912361.3A patent/CN113616661A/zh active Pending
- 2017-03-08 AU AU2017229656A patent/AU2017229656B2/en active Active
- 2017-03-08 CN CN201780027222.4A patent/CN109414444A/zh active Pending
- 2017-03-08 MA MA043815A patent/MA43815A/fr unknown
- 2017-03-08 RU RU2022102537A patent/RU2022102537A/ru unknown
- 2017-03-08 CA CA3017172A patent/CA3017172C/fr active Active
- 2017-03-08 TW TW112108775A patent/TW202400182A/zh unknown
- 2017-03-08 CA CA3158448A patent/CA3158448A1/fr active Pending
- 2017-03-08 KR KR1020187028838A patent/KR102408399B1/ko active IP Right Grant
- 2017-03-08 KR KR1020227019157A patent/KR20220084418A/ko not_active Application Discontinuation
- 2017-03-08 JO JOP/2017/0059A patent/JOP20170059B1/ar active
- 2017-03-08 RU RU2018135079A patent/RU2766155C2/ru active
-
2018
- 2018-09-03 ZA ZA2018/05905A patent/ZA201805905B/en unknown
- 2018-09-06 IL IL261658A patent/IL261658B2/en unknown
- 2018-09-07 PH PH12018501923A patent/PH12018501923A1/en unknown
- 2018-09-07 MX MX2022003896A patent/MX2022003896A/es unknown
-
2019
- 2019-01-18 HK HK19100976.7A patent/HK1258616A1/zh unknown
- 2019-12-18 US US16/718,430 patent/US10940156B2/en active Active
-
2021
- 2021-02-10 JP JP2021019539A patent/JP2021073309A/ja active Pending
- 2021-03-08 US US17/195,129 patent/US11554125B2/en active Active
-
2022
- 2022-12-08 US US18/077,279 patent/US20230355639A1/en active Pending
- 2022-12-09 AU AU2022283769A patent/AU2022283769A1/en active Pending
-
2023
- 2023-04-28 JP JP2023074398A patent/JP2023093723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43815A (fr) | Stéroïdes neuroactifs, compositions, et leurs utilisations | |
| DK3258939T3 (da) | Neuroaktive steroider, sammensætninger og anvendelser heraf | |
| IL292461A (en) | Neuroactive steroids, preparations and their uses | |
| IL285703A (en) | Neuroactive steroids, preparations and their uses | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| DK3021852T3 (da) | Neuroaktive steroider, sammensætninger og anvendelser deraf | |
| DK3488852T3 (da) | Neuroaktive steroider, sammensætninger og anvendelser deraf | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA45943A (fr) | Compositions ignifuges et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA43567A (fr) | Anticorps pacap et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| MA45857A (fr) | Composés et compositions, et utilisations associées | |
| MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
| MA41495A (fr) | Composés benzoxaborole et leurs utilisations | |
| MA43141A (fr) | Nouveaux composés et leurs utilisations | |
| MA46901A (fr) | Agents psychotropes et leurs utilisations | |
| MA45411A (fr) | Compositions antimalariques et leurs utilisations | |
| MA45795A (fr) | Composés et compositions, et utilisations associées | |
| FR3035590B1 (fr) | Complexe proteomelanique bioassimilable, preparation et utilisations | |
| MA45760A (fr) | Bêta-naphthoisoflavones, compositions contenant celles-ci et leurs utilisations | |
| MA45661A (fr) | Anticorps anti-tim3 et leurs utilisations |